The seriousness of disease often results from the strength of immune response, rather than with the virus, itself. Turning down that response, rather than attacking the virus, might be a better way to reduce that severity, says Juliet Morrison of the University of Washington, Seattle. She and her collaborators have now taken the first step in doing just that for the H7N9 influenza, and their work has already led to identification of six potential therapeutics for this highly virulent strain. The research is published ahead of print in the Journal of Virology.
"We set out to characterize the response to the severe disease-causing H7N9 virus and compare it to responses elicited by other serious flu viruses in a mouse model of infection," says Morrison. That work involved determining which genes are turned on by this infection.
"We have found that viruses that cause severe illness, like H7N9 and the infamous 1918 virus, trigger gene expression signatures that are different from the signatures seen in milder infections," says coauthor and University of Washington colleague Michael Katze, in whose laboratory the work was performed. "Importantly, we can exploit these signatures for antiviral drug discovery," he adds.
The investigators then used a computational approach to identify potentially therapeutic drugs. They searched databases containing gene expression profiles of cultured human cells that had been treated with different drugs, in order to find those that were the reverse of expression profiles induced by the H7N9 flu virus, and noting the drugs that accomplished this, says Morrison. These drugs could potentially dampen the harmful host response, she says.
"Six of these drugs are FDA approved and could potentially be repurposed as H7N9 influenza therapeutics," says Morrison. "I believe that computational biology represents an exciting new way to study viruses and to discover drugs to fight them," says Morrison. A
|Contact: Jim Sliwa|
American Society for Microbiology